Prostaglandin E2-induced colonic secretion in patients with and without colorectal neoplasia

BMC Gastroenterology

Volumn 10, Issue , 2010, Pages

  Kaltoft, Nicolai ^a   Tilotta, Maria C ^a   Witte, Anne Barbara ^a,b   Osbak, Philip S ^a   Poulsen, Steen S ^c   Bindslev, Niels ^c   Hansen, Mark B ^a,d  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BUMETANIDE; BUTAPROST; FORSKOLIN; INDOMETACIN; OUABAIN; PROSTAGLANDIN E1; PROSTAGLANDIN E2; PROSTANOID RECEPTOR; SULPROSTONE; THEOPHYLLINE; DRUG DERIVATIVE; INDOMETAFEN; LUBIPROSTONE; PROSTAGLANDIN E RECEPTOR; PROSTAGLANDIN SYNTHASE; TAMOXIFEN;

ADULT; ARTICLE; COLON BIOPSY; COLON MUCOSA; COLON SECRETION; COLONOSCOPY; COLORECTAL CANCER; CONTROLLED STUDY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; ION CONDUCTANCE; MAJOR CLINICAL STUDY; SHORT CIRCUIT CURRENT; SIGMOID; BIOPSY; COLON; COLORECTAL TUMOR; DRUG EFFECT; FEMALE; ION TRANSPORT; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; REFERENCE VALUE; SECRETION; SIGNAL TRANSDUCTION;

ALPROSTADIL; BIOPSY; BUMETANIDE; COLON; COLORECTAL NEOPLASMS; DINOPROSTONE; FEMALE; FORSKOLIN; HUMANS; ION TRANSPORT; MALE; MIDDLE AGED; OUABAIN; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RECEPTORS, PROSTAGLANDIN E; REFERENCE VALUES; SIGNAL TRANSDUCTION; TAMOXIFEN; THEOPHYLLINE;

EID: 77951933004     PISSN: None     EISSN: 1471230X     Source Type: Journal    
DOI: 10.1186/1471-230X-10-9     Document Type: Article

References (43)

1. Gupta RA, Dubois RN. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer 2001, 1:11-21. 10.1038/35094017, 11900248.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin 2008, 58:71-96. 10.3322/CA.2007.0010, 18287387.
3. Backlund MG, Mann JR, Holla VR, Buchanan FG, Tai HH, Musiek ES, Milne GL, Katkuri S, DuBois RN. 15-Hydroxyprostaglandin dehydrogenase is down-regulated in colorectal cancer. J Biol Chem 2005, 280:3217-3223. 10.1074/jbc.M411221200, 1847633, 15542609.
4. Chell S, Kaidi A, Williams AC, Paraskeva C. Mediators of PGE2 synthesis and signalling downstream of COX-2 represent potential targets for the prevention/treatment of colorectal cancer. Biochim Biophys Acta 2006, 1766:104-119.
5. Hilmi I, Goh KL. Chemoprevention of colorectal cancer with nonsteroidal anti-inflammatory drugs. Chin J Dig Dis 2006, 7:1-6. 10.1111/j.1443-9573.2006.00236.x, 16412030.
6. Stack E, Dubois RN. Role of cyclooxygenase inhibitors for the prevention of colorectal cancer. Gastroenterol Clin North Am 2001, 30:1001-1010. 10.1016/S0889-8553(05)70225-9, 11764529.
7. Bennett A. Prostaglandins as factors in diseases of the alimentary tract. Adv Prostaglandin Thromboxane Res 1976, 2:547-555.
8. Mutoh M, Watanabe K, Kitamura T, Shoji Y, Takahashi M, Kawamori T, Tani K, Kobayashi M, Maruyama T, Kobayashi K, et al. Involvement of prostaglandin E receptor subtype EP(4) in colon carcinogenesis. Cancer Res 2002, 62:28-32.
9. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med 2004, 10:789-799. 10.1038/nm1087, 15286780.
10. Lin J, Gan CM, Zhang X, Jones S, Sjöblom T, Wood LD, Parsons DW, Papadopoulos N, Kinzler KW, Vogelstein B, et al. A multidimensional analysis of genes mutated in breast and colorectal cancers. Genome Res 2007, 17:1304-1318. 10.1101/gr.6431107, 1950899, 17693572.
11. Wood LD, Parsons DW, Jones S, Lin J, Sjöblom T, Leary RJ, Shen D, Boca SM, Barber T, Ptak J, et al. The genomic landscapes of human breast and colorectal cancers. Science 2007, 318:1108-1113. 10.1126/science.1145720, 17932254.
12. Shoji Y, Takahashi M, Kitamura T, Watanabe K, Kawamori T, Maruyama T, Sugimoto Y, Negishi M, Narumiya S, Sugimura T, et al. Downregulation of prostaglandin E receptor subtype EP3 during colon cancer development. Gut 2004, 53:1151-1158. 10.1136/gut.2003.028787, 1774140, 15247185.
13. Holla VR, Mann JR, Shi Q, DuBois RN. Prostaglandin E2 regulates the nuclear receptor NR4A2 in colorectal cancer. J Biol Chem 2006, 281:2676-2682. 10.1074/jbc.M507752200, 16293616.
14. Fujino H, Chen X, Regan JW, Murayama T. Indomethacin decreases EP2 prostanoid receptor expression in colon cancer cells. Biochem Biophys Res Commun 2007, 359:568-573. 10.1016/j.bbrc.2007.05.145, 2674506, 17555711.
15. Hawcroft G, Ko CWS, Hull MA. Prostaglandin E2-EP4 receptor signalling promotes tumorigenic behaviour of HT-29 human colorectal cancer cells. Oncogene 2007, 26:3006-3019. 10.1038/sj.onc.1210113, 17130837.
16. Kiriyama M, Ushikubi F, Kobayashi T, Hirata M, Sugimoto Y, Narumiya S. Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol 1997, 122:217-224. 10.1038/sj.bjp.0701367, 1564924, 9313928.
17. Larsen R, Mertz-Nielsen A, Hansen MB, Poulsen SS, Bindslev N. Novel modified Ussing chamber for the study of absorption and secretion in human endoscopic biopsies. Acta Physiol Scand 2001, 173:213-222. 10.1046/j.1365-201X.2001.00865.x, 11683679.
18. Osbak PS, Bindslev N, Poulsen SS, Kaltoft N, Tilotta MC, Hansen MB. Colonic epithelial ion transport is not affected in patients with diverticulosis. BMC Gastroenterol 2007, 7:37. 10.1186/1471-230X-7-37, 2064914, 17888183.
19. Larsen R, Hansen MB, Bindslev N. Duodenal secretion in humans mediated by the EP4 receptor subtype. Acta Physiol Scand 2005, 185:133-140. 10.1111/j.1365-201X.2005.01471.x, 16168007.
20. Mall M, Bleich M, Schurlein M, Kuhr J, Seydewitz HH, Brandis M, Greger R, Kunzelmann K. Cholinergic ion secretion in human colon requires coactivation by cAMP. Am J Physiol 1998, 275:G1274-G1281.
21. Mosa AS, Hansen MB, Tilotta CM, Bindslev N. EP4 and EP2 receptor subtypes involved in colonic secretion in rat. Basic Clin Pharmacol Toxicol 2008, 103:214-221. 10.1111/j.1742-7843.2008.00257.x, 18684231.
22. Rostom A, Dubé C, Lewin G, Tsertsvadze A, Barrowman N, Code C, Sampson M, Moher D. Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force. Ann Intern Med 2007, 146:376-389.
23. Pai R, Nakamura T, Moon WS, Tarnawski AS. Prostaglandins promote colon cancer cell invasion; signaling by cross-talk between two distinct growth factor receptors. FASEB J 2003, 17:1640-1647. 10.1096/fj.02-1011com, 12958170.
24. Greenhough A, Smartt HJM, Moore AE, Roberts HR, Williams AC, Paraskeva C, Kaidi A. The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis 2009, 30:377-386. 10.1093/carcin/bgp014, 19136477.
25. Wang D, DuBois RN. Pro-inflammatory prostaglandins and progression of colorectal cancer. Cancer Lett 2008, 267:197-203. 10.1016/j.canlet.2008.03.004, 2553688, 18406516.
26. Dubois RN. Nonsteroidal antiinflammatory drugs, cyclooxygenase-2, and colorectal cancer prevention. Curr Opin Gastroenterol 2001, 17:65-71. 10.1097/00001574-200101000-00013, 17031153.
27. Brown JR, DuBois RN. COX-2: a molecular target for colorectal cancer prevention. J Clin Oncol 2005, 23:2840-2855. 10.1200/JCO.2005.09.051, 15837998.
28. Fulton AM, Ma X, Kundu N. Targeting prostaglandin E EP receptors to inhibit metastasis. Cancer Res 2006, 66:9794-9797. 10.1158/0008-5472.CAN-06-2067, 17047037.
29. Siemes C, Visser LE, Coebergh JWW, Hofman A, Uitterlinden AG, Stricker BHC. Protective effect of NSAIDs on cancer and influence of COX-2 C(-765G) genotype. Curr Cancer Drug Targets 2008, 8:753-764. 10.2174/156800908786733414, 19075598.
30. Iwama T. NSAIDs and colorectal cancer prevention. J Gastroenterol 2009, 44(Suppl 19):72-76. 10.1007/s00535-008-2265-7, 19148797.
31. Doherty GA, Murray FE. Cyclooxygenase as a target for chemoprevention in colorectal cancer: lost cause or a concept coming of age?. Expert Opin Ther Targets 2009, 13:209-218. 10.1517/14728220802653631, 19236238.
32. Elwood PC, Gallagher AM, Duthie GG, Mur LA, Morgan G. Aspirin, salicylates, and cancer. Lancet 2009, 373:1301-1309. 10.1016/S0140-6736(09)60243-9, 19328542.
33. Kawasaki T, Nosho K, Ohnishi M, Suemoto Y, Glickman JN, Chan AT, Kirkner GJ, Mino-Kenudson M, Fuchs CS, Ogino S. Cyclooxygenase-2 overexpression is common in serrated and non-serrated colorectal adenoma, but uncommon in hyperplastic polyp and sessile serrated polyp/adenoma. BMC Cancer 2008, 8:33. 10.1186/1471-2407-8-33, 2257954, 18230181.
34. McLean MH, Murray GI, Fyfe N, Hold GL, Mowat NAG, El-Omar EM. COX-2 expression in sporadic colorectal adenomatous polyps is linked to adenoma characteristics. Histopathology 2008, 52:806-815. 10.1111/j.1365-2559.2008.03038.x, 18462368.
35. Young LE, Sanduja S, Bemis-Standoli K, Pena EA, Price RL, Dixon DA. The mRNA Binding Proteins HuR and Tristetraprolin Regulate Cyclooxygenase 2 Expression During Colon Carcinogenesis. Gastroenterology 2009, 136:1669-1679. 10.1053/j.gastro.2009.01.010, 19208339.
36. Smith WL, DeWitt DL, Garavito RM. Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem 2000, 69:145-182. 10.1146/annurev.biochem.69.1.145, 10966456.
37. Strillacci A, Griffoni C, Sansone P, Paterini P, Piazzi G, Lazzarini G, Spisni E, Pantaleo MA, Biasco G, Tomasi V. MiR-101 downregulation is involved in cyclooxygenase-2 overexpression in human colon cancer cells. Exp Cell Res 2009, 315:1439-1447. 10.1016/j.yexcr.2008.12.010, 19133256.
38. Holla VR, Backlund MG, Yang P, Newman RA, DuBois RN. Regulation of prostaglandin transporters in colorectal neoplasia. Cancer Prev Res (Phila Pa) 2008, 1:93-99.
39. Backlund MG, Mann JR, Holla VR, Shi Q, Daikoku T, Dey SK, DuBois RN. Repression of 15-hydroxyprostaglandin dehydrogenase involves histone deacetylase 2 and snail in colorectal cancer. Cancer Res 2008, 68:9331-9337. 10.1158/0008-5472.CAN-08-2893, 2628771, 19010907.
40. Yan M, Myung SJ, Fink SP, Lawrence E, Lutterbaugh J, Yang P, Zhou X, Liu D, Rerko RM, Willis J, et al. 15-Hydroxyprostaglandin dehydrogenase inactivation as a mechanism of resistance to celecoxib chemoprevention of colon tumors. Proc Natl Acad Sci USA 2009, 106:9409-9413. 10.1073/pnas.0902367106, 2695050, 19470469.
41. Gradilone A, Pulcinelli FM, Lotti LV, Trifirò E, Martino S, Gandini O, Gianni W, Frati L, Aglianò AM, Gazzaniga P. Celecoxib upregulates multidrug resistance proteins in colon cancer: lack of synergy with standard chemotherapy. Curr Cancer Drug Targets 2008, 8:414-420. 10.2174/156800908785133178, 18690847.
42. Bijvelds MJ, Bot AG, Escher JC, De Jonge HR. Activation of intestinal Cl- secretion by lubiprostone requires the cystic fibrosis transmembrane conductance regulator. Gastroenterology 2009, 137:976-985. 10.1053/j.gastro.2009.05.037, 19454284.
43. Mizumori M, Akiba Y, Kaunitz JD. Lubiprostone stimulates duodenal bicarbonate secretion in rats. Dig Dis Sci 2009, 54:2063-2069. 10.1007/s10620-009-0907-0, 2737111, 19657734.